Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04721353 · ClinicalTrials.gov registry record · Phase 4
Reducing Cannabis Overuse With Prazosin
A Phase 4 study of Post Traumatic Stress Disorder and Cannabis Use Disorder, sponsored by VA Puget Sound Health Care System.
- Completed
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT04721353: Completed Phase 4 study of Post Traumatic Stress Disorder and Cannabis Use Disorder, sponsored by VA Puget Sound Health Care System.
NCT04721353 is a Phase 4 study of Post Traumatic Stress Disorder and Cannabis Use Disorder that has completed, run by VA Puget Sound Health Care System. The registered enrollment target is 11 participants, below the 664-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04721353, a Phase 4 study of Post Traumatic Stress Disorder and Cannabis Use Disorder, has completed, sponsored by VA Puget Sound Health Care System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
Cannabis use disorder (CUD) is a significant and expanding health problem, and no FDA approved treatments are currently available. Persons with posttraumatic stress disorder (PTSD) may use cannabis to help control symptoms. Relief from PTSD insomnia, nightmares, anxiety, and preoccupying thoughts have been reported as troublesome symptoms targeted by cannabis users. Risks from cannabis use by individuals with PTSD have been reported. Chronic use of cannabis can lead to tolerance, requiring increased use for symptom relief, and withdrawal symptoms upon stopping. CUD is more frequent and severe in those with PTSD than those without. Many symptoms of cannabis withdrawal overlap with troubling symptoms of PTSD and thus may be interpreted as a relapse of PTSD symptoms. Those attempting to reduce or stop cannabis use may experience cannabis withdrawal symptoms including insomnia and distressing dreams, anxiety, irritability, and/or excessive sweating that they may misattribute to re-emerging or untreated PTSD symptoms. Excessive brain adrenaline activity is arguably the best-described neurobiological contribution to the pathophysiology of PTSD. Prazosin, a drug that blocks the negative effects of brain adrenaline, has demonstrated effectiveness in robustly reducing PTSD-related nightmares and sleep disturbance in active duty Servicemembers and recently discharged combat Veterans in most, but not all, clinical trials, as well as in civilians with non-combat trauma. Clinically, the investigators have observed that several patients with PTSD using cannabis to treat insomnia and/or trauma-related nightmares and wanting to reduce their cannabis use were able to achieve reduction or cessation of cannabis use once they were treated with an effective dose of prazosin. Therefore, we have wondered if prazosin may provide sufficient treatment of PTSD symptoms otherwise targeted by cannabis, supporting those individuals' efforts to reduce cannabis use. This open-label pilot study a
Primary Outcome
Proportion of potential participants referred to the study meeting inclusion/exclusion criteria and complete the baseline visit
Conditions Studied
Interventions
- DRUG Prazosin Hydrochloride
Study Locations (1)
Washington
- VA Puget Sound Health Care System - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2020-11-09 |
| Est. Completion | 2025-06-01 |
| Phase | Phase 4 |
What the finished NCT04721353 record still lists
NCT04721353 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 664-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Post Traumatic Stress Disorder appearing as the primary indexed condition, and to 1 intervention - of which Prazosin Hydrochloride is the first listed.
NCT04721353 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT04721353 about?
NCT04721353 is a clinical study titled "Reducing Cannabis Overuse With Prazosin". Cannabis use disorder (CUD) is a significant and expanding health problem, and no FDA approved treatments are currently available. Persons with posttraumatic stress disorder (PTSD) may use cannabis to help control symptoms. Relief from PTSD insomnia, nightmares, anxiety, and preoccupying thoughts ha...
What is the current status of trial NCT04721353?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2020-11-09. Estimated completion is 2025-06-01.
What conditions does trial NCT04721353 study?
This clinical trial studies the following conditions: Post Traumatic Stress Disorder, Cannabis Use Disorder, Cannabis Dependence.
What interventions are being tested in trial NCT04721353?
The interventions under investigation include: Prazosin Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT04721353?
This trial is sponsored by VA Puget Sound Health Care System, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04721353 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post Traumatic Stress Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04721353's enrollment target sits among peer trials
11 250th of 262 higher than 13 of 262 other Post Traumatic Stress Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Post Traumatic Stress Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effects of Stellate Ganglion Block in Post-traumatic Stress Disorder
RECRUITING · Phase 4
-
An Open Label Pilot Study of IV Brexanolone for the Treatment of Post-Traumatic Stress Disorder
RECRUITING · Phase 4
-
A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD
ACTIVE NOT RECRUITING · Phase 4
-
Short Course Glucocorticoid Treatment for PTSD
COMPLETED · Phase 4
-
Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy
COMPLETED · Phase 4
-
Effect of Propranolol on Preventing Posttraumatic Stress Disorder
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI